, Volume 63, Issue 19, pp 2013–2026 | Cite as


In the Treatment of Essential Hypertension
  • Caroline Fenton
  • Gillian M. Keating
  • Lesley J. Scott
Adis Drug Profile


  • ▴ Oral telmisartan/hydrochlorothiazide (HCTZ) combines two antihypertensive agents, a selective angiotensin II receptor antagonist with a long half-life and once-daily administration, and a thiazide diuretic.

  • ▴ In two large, 8-week, double-blind trials, patients with hypertension unresponsive to monotherapy who received combined telmisartan/HCTZ 80/12.5 or 40/12.5 mg/day, achieved significantly larger reductions in diastolic and systolic blood pressure (BP), than recipients of continued telmisartan monotherapy (p < 0.05 for all). Compliance with telmisartan/HCTZ 80/12.5 mg/day was 98.9%.

  • ▴ In patients with hypertension, telmisartan/HCTZ resulted in similar BP reductions to oral enalapril/ HCTZ and atenolol/HCTZ in 26-week double-blind trials and greater reductions than oral losartan/ HCTZ 50/12.5 mg/day in a 6-week randomised open-label trial (p < 0.001).

  • ▴ Up to one-third of patients with hypertension initially responsive to telmisartan 40 or 80 mg/day in a 4-year study required the eventual addition of HCTZ 12.5 or 25 mg/day and/or another agent to maintain BP control. BP was controlled in about 75% of these by adding only HCTZ.

  • ▴ In clinical trials of up to 4 years, including elderly patients, telmisartan/HCTZ had similar tolerability to placebo, with few reports of hypokalaemia. Most adverse events were mild to moderate.


Enalapril Atenolol Losartan Telmisartan HCTZ 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001 Jun; 23(6): 833–50PubMedCrossRefGoogle Scholar
  2. 2.
    Freytag F, Holwerda NJ, Karlberg BE, et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11(3): 173–81PubMedCrossRefGoogle Scholar
  3. 3.
    Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002 Mar–Apr; 9(2): 111–7PubMedCrossRefGoogle Scholar
  4. 4.
    Lacourcière Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res 2002 Jul–Aug; 30(4): 366–79PubMedGoogle Scholar
  5. 5.
    Lacourcière Y, Tytus R, O’Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan mono-therapy. J Hum Hypertens 2001 Nov; 15(11): 763–70PubMedCrossRefGoogle Scholar
  6. 6.
    Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61(10): 1501–29PubMedCrossRefGoogle Scholar
  7. 7.
    Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002 Sep; 302(3): 1089–95PubMedCrossRefGoogle Scholar
  8. 8.
    Balt JC, Mathy MJ, Nap A, et al. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol 2001 Jul; 38(1): 141–8PubMedCrossRefGoogle Scholar
  9. 9.
    Stangier J, Su CA, van Heiningen PN, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001 Nov; 38(5): 672–85PubMedCrossRefGoogle Scholar
  10. 10.
    Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 Jan; 41: 31–6PubMedCrossRefGoogle Scholar
  11. 11.
    Burgess ED, Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients [abstract no. 1025]. Am J Hypertens 2000 Apr; 13 (Pt 2): 183Google Scholar
  12. 12.
    Burgess ED, Buckley S. Long-term effect of telmisartan on sodium excretion in hypertensive patients [abstract no. 58]. Can J Cardiol 2000 Sep; 16 Suppl. F: 106Google Scholar
  13. 13.
    Weber M. The telmisartan programme of research to show telmisartan end-organ protection (PROTECTION) programme. J Hypertens 2003; 21 Suppl. 6: S37–46Google Scholar
  14. 14.
    Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303PubMedCrossRefGoogle Scholar
  15. 15.
    Ripley E, King K, Sica DA. Racial differences in response to acute dosing with hydrochlorothiazide. Am J Hypertens 2000; 13(2): 157–64PubMedCrossRefGoogle Scholar
  16. 16.
    van Brummelen P, Man in ’t Veld AJ, Schalekamp MADH. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and non-responders. Clin Pharmacol Ther 1980 Mar; 27(3): 328–36PubMedCrossRefGoogle Scholar
  17. 17.
    Pickkers P, Hughes AD, Russel FGM, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998 Dec; 32: 1071–6PubMedCrossRefGoogle Scholar
  18. 18.
    Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effect of hydrochlorothiazide. Hypertension 1999 Apr; 33: 1043–8PubMedCrossRefGoogle Scholar
  19. 19.
    Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 2001 Jun; 2(2): 123–8PubMedGoogle Scholar
  20. 20.
    Yong CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1323–30Google Scholar
  21. 21.
    Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1312–22Google Scholar
  22. 22.
    Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000 Jul–Aug; 28: 149–67PubMedGoogle Scholar
  23. 23.
    Neutel JM, Smith DHG, Telmisartan US Study Group. Dose response and antihypertensive efficacy of the AT1receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998 Jul–Aug; 15: 206–17Google Scholar
  24. 24.
    Stangier J, Su C-APF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1355–64PubMedGoogle Scholar
  25. 25.
    Stangier J, Heinzel G, Su C-A, et al. Clinical pharmacokinetics of telmisartan [abstract no. P.49]. J Hum Hypertens 1999 May; 13 Suppl. 3: 13Google Scholar
  26. 26.
    Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984 Mar; 73(3): 359–61PubMedCrossRefGoogle Scholar
  27. 27.
    Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. J Pharm Sci 1982 Feb; 71(2): 245–8PubMedCrossRefGoogle Scholar
  28. 28.
    Chen TM, Chiou WL. Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol 1992 Jan; 30(1): 34–7PubMedGoogle Scholar
  29. 29.
    Niemeyer C, Hasenfuss G, Wais U, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 1983; 24(5): 661–5PubMedCrossRefGoogle Scholar
  30. 30.
    Boehringer Ingelheim. Telmisartan prescribing information. 2000Google Scholar
  31. 31.
    Stangier J, Su C-APF, Brickl R, et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1365–72PubMedGoogle Scholar
  32. 32.
    Hannedouche T, Chanard J, Baumelou B. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001 Dec; 2(4): 246–54PubMedCrossRefGoogle Scholar
  33. 33.
    Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol 1979 Jun; 7(6): 579–83PubMedCrossRefGoogle Scholar
  34. 34.
    Lacourcière Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003 May; 57: 237–79Google Scholar
  35. 35.
    Neutel JM, Klein C, Meinicke TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11(5): 302–9PubMedCrossRefGoogle Scholar
  36. 36.
    Freytag F, Schelling A, Meinicke T, et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001 Jan; 23(1): 108–23PubMedCrossRefGoogle Scholar
  37. 37.
    Karlberg BE, Lins L-E, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17(2): 293–302PubMedCrossRefGoogle Scholar
  38. 38.
    McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001 Jan; 24(1): 66–72PubMedCrossRefGoogle Scholar
  39. 39.
    Boehringer-Ingelheim. Data on file. 2003Google Scholar
  40. 40.
    Lacourcière Y, Poirier L, Extremera BG, et al. Telmisartan in combination with hydrochlorothiazide or losartan in combination with hydrochlorothiazide; ABPM assessment of blood pressure lowering. Am J Hypertens 2002 Apr; 15 (Pt 2): 113Google Scholar
  41. 41.
    Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo [abstract no. R194]. J Hypertens 2002 Jun; 20 (4 Suppl.): 377Google Scholar
  42. 42.
    European Agency for the Evaluation of Medicinal Products. Summary of product characteristics for telmisartan/hydrochlorothiazide [online]. Available from URL: [Accessed 2003 May 20]

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Caroline Fenton
    • 1
  • Gillian M. Keating
    • 1
  • Lesley J. Scott
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations